retail news in context, analysis with attitude

The New York Times has an interesting story about Martin Shkreli, who was CEO at Turing Pharmaceuticals when it increased the price of Daraprim, a drug used to treat a life-threatening parasitic infection, from $13.50 per tablet to $750. Shkreli became a kind of cultural pariah when he defended the increase - which put the drug out of reach for many patients - as being justified, and he resigned the CEO job after he was indicted in December for securities fraud related to a hedge fund he used to run.

The story is about how Shkreli, who is a frequent user of social media sites as a method of explaining himself and his positions, is simultaneously refusing to testify under oath before Congress, citing his Constitutional right not to incriminate himself. And the tension between social media and subpoenaed testimony has never been so palpable ... and you can read more about it here.
KC's View: